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Synthesis of highly substituted 2-spiropiperidines  
Samuel D. Griggs,
a
 Nathan Thompson,
a
 Daniel T. Tape,
b
 Marie Fabre
a
 and Paul. A. Clarke*
a
 
 
2-Spiropiperidines are a highly desirable, yet under represented structure in drug discovery. 2-Spiropiperidines were 
synthesised in either a two-pot or one-pot reaction. In the two-pot reaction, the addition of a Weiler dianion to N-Boc 
imines, followed by deprotection and in situ condensation with a cyclic ketone generated functionalised 2-spiropiperidines 
in good to excellent yields. In the one-pot reaction, the addition of Chan’s diene to N-Boc imines under Maitland-Japp 
conditions, followed by the addition of sodium bicarbonate and a cyclic ketone formed functionalised 2-spiropiperidines in 
moderate to good yields.  
Introduction 
Spiropiperidines are an increasingly important structural unit, 
appearing in both natural products and drug discovery 
programs.
1
 In the natural product arena they are present in 
several alkaloid classes, including histrionicotoxin,
2
 
nankakurine,
3
 pinnaic acid,
4
 etc. Within the context of drug 
discovery they are desired due to their well-defined 
conformations, and novel intellectual property value.
5
 For 
these reasons over the last few years an increasing number of 
routes for their synthesis have been described.
1, 6
 However, 
the majority of these routes are directed at providing access to 
3- or 4-spiropiperidines, with limited methods available for the 
synthesis of 2-spiropiperidines.
6
 Those methods available for 
the formation of 2-spiropiperidines rely either on the use of 
toxic organotin-reagents,
7
 alkylation and reductive cyclisation 
of aminonitriles,
8
 or ring-closing metathesis,
9
 and often require 
the prior synthesis of advanced precursors.  
We previously reported the synthesis of highly substituted 
piperidines via a modification of the Maitland-Japp 
tetrahydropyran synthesis; the replacement of an aldehyde 
with either an N-aryl
10, 11 
or N-tosyl imine.
12
 N-Aryl imines were 
formed in situ from anilines and aryl ketones in the same pot 
as N-aryl enamines, formed by the condensation of anilines 
with β-ketoesters. The N-aryl-β-enaminoester underwent 
Stork enamine-like condensation
13
 with the N-aryl imines and 
cyclisation to form highly substituted piperidines (Scheme 
1A).
10, 11
 N-Tosyl imines were reacted with diketene to form δ-
amino-β-ketoesters which were treated in situ with an 
aldehyde to generate highly substituted non-symmetrical 
piperidines (Scheme 1B).
12
 Given our previous contributions to 
the synthesis of piperidines and the increasing interest in the 
synthesis of spiropiperidines, we decided to investigate the 
modification of these processes to enable the synthesis of 2-
spiropiperidines.
14 
Scheme 1 Maitland-Japp syntheses of highly functionalised piperidines 
Results and discussion 
Initial investigations with N-tosyl imines 
Due to the lack of availability of diketene, our initial study 
forced us to use the dianion of methyl acetoacetate,
15
 which 
was added to the N-tosyl imine of benzaldehyde 1. It was 
hoped that the resultant δ-amino-β-ketoester 2, which was 
formed in 44% yield could be cyclised onto a ketone (acetone) 
under Maitland-Japp conditions.
12, 16
 Treatment of δ-amino-β-
ketoester 2 with acetone, TiCl4 and pyridine in THF led only to 
the isolation of the Knoevenagel product 3 in 26% yield and re-
isolated 2. Submission of δ-amino-β-ketoester 3 to TiCl4 in 
CH2Cl2 and stirring for an extended period of time led to 
elimination of tosyl amide, and the formation of 4; no 
cyclisation to the piperidine was observed (Scheme 2).  
The identity of 4 was confirmed via its synthesis from δ-
hydroxy-β-ketoester 6. δ-Hydroxy-β-ketoester 6
17
 was treated 
with Ac2O, Et3N, DMAP in CH2Cl2 at room temperature, which 
resulted in acylation of the hydroxyl and concomitant 
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elimination of acetic acid. Enone 5 was then subjected to 
Maitland-Japp conditions (TiCl4, acetone, pyridine in THF) 
which led to the formation of 4 in 13% yield (Scheme 2), the 
spectroscopic data of which was identical to that formed 
through the elimination of tosyl amide from 3.  
Scheme 2 Attempted cyclisation with N-tosyl amine 2 and acetone 
It was disheartening that cyclisation conditions which yielded 
piperidines with N-tosyl amines and aldehydes did not 
generate piperidines when ketones were used. We believe 
that this is due to a destabilising interaction in the transition 
state, not present in the cyclisation with aldehydes (Fig. 1). If 
cyclisation were to occur via TS1 then there is a 1,3-diaxial 
interaction between the Ph-group and the axial Me-group. The 
alternative chair conformation TS2 suffers from an A1,2-like 
destabilising interaction between the N-tosyl group and the 
equatorial Me-group.   
 
 
 
 
 
Fig 1 Destabilising interactions which disfavour cyclisation of 3. Proton on N 
omitted for clarity 
Attempts to deprotect 3 with Mg/MeOH,
18
 and hence form the 
free amine for cyclisation, resulted in decomposition of the 
substrate and so the further use of N-tosyl imines was 
abandoned. Our attention turned to the use of N-Boc imines, 
which we reasoned could be synthesised efficiently and easily 
deprotected.  
 
Two-pot synthesis of 2-spiropiperidines 
Known aryl N-Boc imines were prepared from the appropriate 
aryl aldehyde according to literature procedures,
19-21
 and were 
isolated. These aryl N-Boc imines were treated with the Weiler 
dianion of methyl acetoacetate
15
 to generate δ-N-Boc-amino-
β-ketoesters. Other N-Boc imines proved to be too unstable to 
be isolated and were generated in situ from their N-Boc 
sulfone precursor 7. In these cases 3 eq. of NaH was used to 
form the N-Boc imine in situ before the addition of the Weiler 
dianion, which led to the formation of the the δ-N-Boc-amino-
β-ketoesters 9. This procedure was so facile that it became our 
standard protocol for all N-Boc imines used, including those 
which were stable enough to be isolated. It was found that 
these δ-N-Boc-amino-β-ketoesters 8 could be isolated and 
stored for several weeks without detriment. Cyclisation of δ-N-
Boc-amino-β-ketoesters 8 was achieved by removal of the N-
Boc group with HCl in dioxane to form the HCl salt. The HCl salt 
was “cracked” with NaHCO3 in the presence of a ketone 9, 
which promoted cyclisation and yielded the desired 2-
spiropiperidine 10 (Scheme 3, Table 1 and Table 2).  
Scheme 3 Two-step synthesis of 2-spiropiperidines 10 
Table 1 Synthesis of δ-N-Boc-amino-β-ketoesters 9 
N-Boc sulfone 7 R Yield 9 (%) 
a Me 76 
b Pr 65 
c iPr 50 
d Ph 73 
e 4-FC6H4 77 
f 4-MeOC6H4 53 
g 3-pyridyl 56 
h methyl thiazole 58 
i N-methyl pyrazole 57 
j 4-CNC6H4 68 
 
Page 2 of 12Organic & Biomolec lar Chemistry
2U
JD
QLF
	%
LRP
ROH
FX
ODU
&K
HP
LVW
U\
$F
FH
SWH
G0
DQ
XV
FUL
SW
Pu
bl
ish
ed
 o
n 
30
 Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f Y
or
k 
on
 7
/3
1/
20
18
 9
:5
0:
48
 A
M
. 
View Article Online
DOI: 10.1039/C8OB01272E
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3 
Please do not adjust margins 
Please do not adjust margins 
Table 2 Synthesis of 2-spiropiperidines 10 
Entry 9 R Ketone 10 Yield 11 
(%) 
dr
a
 11 
a a Me acetone 85 2.5:1 
b a Me cyclohexanone 85 7:1 
c a Me cyclopentanone 43 5:1 
d a Me cyclobutanone 57 2.5:1 
e a Me 4-pyranone 59 4.5:1 
f d Ph cyclohexanone 78 7:1 
g e 4-FC6H4 acetone 97 1.8:1 
h e 4-FC6H4 cyclohexanone 75 5:1 
i e 4-FC6H4 4-pyranone 56 2:1 
j e 4-FC6H4 4-thiopyranone 63 1:1 
k f 4-MeOC6H4 4-pyranone 33 2:1 
l g 3-pyridyl acetone 86 1.5:1 
m g 3-pyridyl 4-pyranone 76 1.5:1 
n g 3-pyridyl N-Cbz-4-piperidone 67 2:1 
o g 3-pyridyl 4-thiopyranone 75 0.95:1 
p h methyl thiazole 4-pyranone 75 1:1 
q i N-methyl pyrazole 4-pyranone 50 2.5:1 
r j 4-CNC6H4 cyclobutanone 63 1:1 
s j 4-CNC6H4 2-oxetanone 43 1.6:1 
a) The ratio of diastereomers was determined by 
1
H NMR analysis of the crude 
reaction mixture. In most cases the β-CO2Me diastereomer dominated and is 
report first in the dr ratio. 
A range of δ-N-Boc-amino-β-ketoesters 9 were prepared 
(Table 1) from N-Boc sulfone precursors 7 derived from 
aliphatic (7a-c) and aromatic aldehydes (7d-j), including 
several from the GSK aldehyde library.
22 
Aldehydes were 
selected after discussions with GSK, which highlighted 
compounds that would be of interest to medicinal chemists. 
Selected aldehyde derivatives included thiazole, pyrazole, 
pyridyl functionality and substituted aromatics (7e-j). All were 
isolated in good yields. Acetone and a selection of cyclic 
ketones (four to six membered rings), including N-, O- and S-
heteroatom-containing cyclic ketones, all underwent smooth 
cyclisation with δ-N-Boc-amino-β-ketoesters 9 to form 2-
spiropiperidines 11a-s in good to excellent yields. The 
piperidines were formed as a mixture of diasteromeric methyl 
esters, and there was no evidence that the diastereomeric 
esters interconverted during isolation and purification. In most 
examples the major diastereomer was determined to have the 
axial β-ester group. In the representative case of 11e H-3 (δ 
3.39 ppm) displayed a ‘W-coupling’ of 1.0 Hz to H-5α (δ 2.64 
ppm) indicating both their equatorial positions. A coupling 
constant of 3.5 Hz was seen between H-5α and H-6α indicating 
a syn-relationship, while there was an 11.5 Hz coupling 
between H-6α and H-5β (δ 3.06 ppm) indicating an anti-
relationship (Fig 2). This stereochemical arrangement was 
confirmed by an X-ray crystal structure of 11i
ǂ
 (Fig. 3). 
Presumably the ester group is axial to avoid a destabilising 
steric interaction with the protons on the adjacent spiro-ring.  
 
 
 
 
 
 
 
 
 
 
 
Fig 2 
1
H NMR data supporting the formation of 11e β-CO2Me diastereomer 
 
 
Fig 3 X-ray crystal structure of 11i showing the axial methyl ester
ǂ
 
 
One-pot synthesis of 2-spiropiperidines 
With a two-pot procedure for the synthesis of 2-
spiropiperidines realised, attention turned to the re-
development of a one-pot procedure. Previous studies had led 
to the development of a one-pot Maitland-Japp synthesis of 
piperidines
12
 (Scheme 1B), however; the lack of availability of 
diketene necessitated the use of an alternative nucleophile. As 
one variant of the one-pot Maitland-Japp synthesis of 
tetrahydropyrans (THPs) had utilised the bis-silyl enolether of 
methyl acetoacetate
17
 (Chan’s diene 13) it was decided to 
investigate this as the nucleophile. It was also decided to 
investigate the addition and cyclisation steps independently at 
first in order to ensure both reactions were viable. As TiCl4 had 
promoted the addition of Chan’s diene to aldehydes, that was 
examined first.  It was found that TiCl4 promoted the addition 
of Chan’s diene to N-Boc imine 11e to form δ-N-Boc-amino-β-
ketoester 9e in 61% yield. However, submission of 9e to TiCl4 
in the presence of cyclohexanone did not result in cyclisation 
at either -78 °C or RT, and only the re-isolation of 9e (Scheme 
4).  
Scheme 4: Attempted one-pot synthesis of 2-spiropiperidine 10h 
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It was rationalised that the N-Boc group was inhibiting the 
cyclisation both electronically and sterically, and we were 
somewhat surprised that it remained intact in the presence of 
TiCl4 at RT. To solve this problem and develop a one-pot 
method, conditions had to be devised to affect removal of the 
N-Boc group under conditions compatible with both the 
Mannich-like addition and cyclisation reactions. It was 
rationalised that the addition of MeOH to the reaction after 
the formation of 9e would generate HCl by methanolysis of the 
TiCl4. The HCl generated in situ would remove the N-Boc 
group, revealing the amine as the HCl salt. At this stage, 
addition of a base and a ketone should free the amine and 
initiate cyclisation to 11h.
14
 Indeed, when 12e was treated 
with Chan’s diene and TiCl4 at -78 °C, Mannich-like addition 
occurred to generate 9e (by TLC). At this point MeOH was 
introduced to the reaction and the temperature was raised to 
RT. After a short while both cyclohexanone and NaHCO3 were 
added to the reaction and stirred at RT. This procedure yielded 
11h after work up and purification in 61% yield (Scheme 5). It 
is worth noting that the two-step procedure yielded 11h in 
57% yield over the two steps. 
 
Scheme 5 Successful one-pot synthesis of 2-spiropiperidine 10h 
With a one-pot procedure developed its scope was explored 
using several different δ-N-Boc-imines 12 and ketones 10 
(Table 3). For the majority of cases (entry 1-4, 6 and 7) the 
one-pot reaction generated 2-spiropiperidines in moderate to 
good yields, and in examples 11h, 11i, 11k and 11p these were 
higher yields than for the two-pot procedure. 2-
Spiropiperidines 11t, 11u, 11v, 11w and 11x (entries 6-10) had 
not been synthesised previously by the two-pot method. In the 
cases of entries 7 and 8, the diastereomeric ratio of 11u and 
11v had to be determined after silica plug filtration due to the 
overlapping peaks of some impurities. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 One-pot synthesis of 2-spiropiperidines 10 
 
Entry Ar 12 Ketone 10 Yield 
11 (%) 
dr
a
 11 
1 e p-FC6H4 cyclohexanone h 61 5:1 
2 e p-FC6H4 4-pyranone i 69 2:1 
3 f p-MeOC6H4 4-pyranone k 62 1.5:1 
4 h methyl thiazole 4-pyranone p 49 2.5:1 
5 j 4-CNC6H4 cyclobutanone r 37 3.5:1 
6 h methyl thiazole 4-thiopyranone t 55 3:1 
7 h methyl thiazole N-Cbz-4-piperidone u 45 2.5:1
b
 
8 j 4-CNC6H4 N-Cbz-4-piperidone v 24 4:1
b
 
9 k 4-CF3C6H4 cyclohexanone w 28 1.5:1 
10 h methyl thiazole acetone x 24 1:1.5
c 
a) The ratio of diastereomers was determined by 
1
H NMR analysis of the crude 
reaction mixture. In most cases the β-CO2Me diastereomer dominated and is 
report first in the dr ratio. b) The ratio of diastereomers was determined by 
1
H 
NMR analysis after silica plug chromatography. c) α-CO2Me was the major 
diastereomer. 
Interestingly the major product in the formation of 11x (entry 
10) was the α-CO2Me diastereomer. The diastereomeric ratio 
did not change upon resubmission to the reaction conditions. 
The configuration of this diastereomer was determined by 
comparison of the chemical shifts of H3 and H5β, along with 
their coupling constants. The proton H3 (δ 3.60 ppm) appeared 
as a singlet and at a chemical shift reminiscent of the minor 
diastereomers formed in other examples. The proton assigned 
as H5β had a chemical shift of δ 2.40 ppm and a coupling 
constant of 11.0 Hz to H6α, indicating their trans-diaxial 
relationship (Fig 4). 
 
 
 
 
 
 
 
 
 
Fig 4 
1
H NMR data supporting the formation of 11x α-CO2Me diastereomer 
Conclusions 
Simple and robust two-pot and one-pot procedures for the 
synthesis of 2-spiropiperidines have been developed. These 
methods are applicable to a large range of differently 
functionalised 2-spiropiperidines, and allow for the synthesis 
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of piperidines spirofused to 4-, 5-, and 6-membered carbo- and 
heterocyclic rings and substituted at the C3 and C6 positions of 
the piperidine ring. The ease of these procedures will allow the 
evaluation of 2-spiropiperidnes in drug discovery programs 
and they will be of use in the synthesis of spirocyclic alkaloid 
natural products. 
 
Experimental 
General 
Unless otherwise noted all compounds were bought from 
commercial suppliers and used without further purification. 
Where a solvent is described as “dry” it was purified by 
PureSolv alumina columns from Innovative Technologies.  
Melting points were determined using a Stuart SMP3 
apparatus. Infra-red spectra were acquired on a 
ThermoNicolet Avatar 370 FT-IR spectrometer. Nuclear 
magnetic resonance spectra were recorded on a Jeol ECS-400, 
a Jeol 500 Avance III HD 500 or a Jeol AV500 at ambient 
temperature. Coupling constants (J) are quoted in Hertz. Mass 
spectrometry was performed by the University of York mass 
spectrometry service using electron spray ionisation (ESI) 
technique. Thin layer chromatography was performed on 
glass-backed plates coated with Merck Silica gel 60 F254. The 
plates were developed using ultraviolet light, acidic aqueous 
ceric ammonium molybdate or basic aqueous potassium 
permanganate. Liquid chromatography was performed using 
forced flow (flash column) with the solvent systems indicated. 
The stationary phase was silica gel 60 (220–240 mesh) supplied 
by Fluorochem or silica gel Merck TLC grade 11695 supplied by 
Sigma-Aldrich.  
 
General procedure for the synthesis of benzenesulfonyl carbamic 
esters 7
21
 
To a solution of aldehyde (53.6 mmol) in water, methanol and 
formic acid (2:1:0.7, 142 mL) was added tert-butyl carbamate 
(35.7 mmol) and benzenesulfinic acid sodium salt (71.4 mmol). 
The mixture was stirred at room temperature for 3 days. The 
precipitate was filtered and washed with water (150 mL) and 
hexane (300 mL).  
 
(1-Benzenesulfonyl-ethyl)-carbamic acid tert-butyl ester (7a) 
Acetaldehyde (3 mL, 53.6 mmol) yielded 8.27 g (81%) as a 
white solid. Spectroscopic data was identical to that previously 
reported.
23 
mp 129-131 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 7.94-
7.85 (m, 2H), 7.66-7.58 (m, 1H), 7.57-7.48 (m, 2H), 5.08 (d, J = 
10.5 Hz, 1H), 4.99 (dq, J = 10.5, 7.0 Hz, 1H), 1.62 (d, J = 7.0 Hz, 
3H), 1.20 (s, 9H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 153.5, 
136.7, 134.0, 129.5, 129.2, 80.9, 66.9, 28.1, 13.0 ppm; IR (ATR): 
νmax 3337, 2973, 1691, 1518, 1313, 1145 cm
-1
; HRMS (ESI) 
308.0918 (M + Na
+
. C13H19NNaO4S requires 308.0927). 
 
(1-Benzenesulfonyl-butyl)-carbamic acid tert-butyl ester (7b) 
Butyraldehyde (1.15 mL, 12.8 mmol) yielded 1.33 g (50%) as a 
white solid; mp 117-118 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 7.91-
7.86 (m, 2H), 7.62-7.56 (m, 1H), 7.54-7.47 (m, 2H), 5.07 (d, J = 
11.0 Hz, 1H), 4.84 (td, J = 11.0, 3.5 Hz, 1H), 2.24-2.13 (m, 1H), 
1.79-1.65 (m, 1H), 1.62-1.48 (m, 1H), 1.46-1.35 (m, 1H), 1.24 (s, 
9H), 0.95 (t, J = 7.5 Hz, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 
153.9, 137.1, 133.9, 129.4, 129.1, 80.8, 70.7, 28.3, 28.1, 18.8, 
13.6 ppm; IR (ATR): νmax 3286, 2960, 2874, 1690, 1526, 1310, 
1246, 1144, 1083 cm
-1
; HRMS (ESI) 336.1243 (M + Na
+
. 
C15H23NNaO4S requires 336.1240). 
 
(1-Benzenesulfonyl-2-methyl-propyl)-carbamic acid tert-butyl 
ester (7c) 
Isobutyraldehyde (4.67 mL, 51.3 mmol) yielded 4.93 g (47%) as 
a white solid. Spectroscopic data was identical to that 
previously reported.
24
 mp 116-117.5 
o
C; 
1
H NMR (400 MHz, 
CDCl3): δ 7.91-7.86 (m, 2H), 7.64-7.58 (m, 1H), 7.55-7.49 (m, 
2H), 5.14 (d, J = 11.0 Hz, 1H), 4.84 (dd, J = 11.0, 3.5 Hz, 1H), 
2.82-2.73 (m, 1H), 1.22 (s, 9H), 1.14 (d, J = 7.0 Hz, 3H), 1.07 (d, 
J = 7.0 Hz, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 154.2, 138.2, 
133.8 , 129.2, 129.1, 80.9, 74.4, 28.1, 26.8, 20.8, 17.0 ppm; IR 
(ATR): νmax 3356, 3232, 3142, 2965, 1704, 1364, 1307, 1141, 
1082 cm
-1
; HRMS (ESI) 226.1404 (M + Na
+
. C10H21NNaO3 
requires 226.1414 for the methanol adduct (-SO2Ph, +OMe)). 
 
(Benzenesulfonyl-phenyl-methyl)-carbamic acid tert-butyl ester 
(7d) 
Benzaldehyde (1.52 mL, 15 mmol) yielded 3.26 g (94%) as a 
white solid. Spectroscopic data was identical to that previously 
reported.
19
 mp 158-161 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 7.92 
(d, J = 7.5 Hz, 2H), 7.64 (dd, J = 7.5, 7.5 Hz, 1H), 7.53 (dd, J = 
7.5, 7.5 Hz, 2H), 7.48-7.39 (m, 5H), 5.94 (d, J = 10.5 Hz, 1H), 
5.87 (d, J = 10.5 Hz, 1H), 1.25 (s, 9H) ppm; 
13
C NMR (101 MHz, 
CDCl3): δ 153.6, 137.0, 134.1, 130.0, 129.6, 129.2, 129.1, 128.9, 
125.1, 81.4, 74.0, 28.1 ppm; IR (ATR): νmax 3355, 3274, 2978, 
1693, 1508, 1306, 1141 cm
-1
; HRMS (ESI) 260.1257 (M + Na
+
. 
C13H19NNaO3 requires 260.1257 for the methanol adduct (-
SO2Ph, +OMe)). 
 
[Benzenesulfonyl-(4-fluoro-phenyl)-methyl]-carbamic acid tert-
butyl ester (7e) 
4-Fluorobenzaldehyde (9.61 mL, 90.0 mmol) yielded 19.9 g 
(91%) as a white solid. Spectroscopic data was identical to that 
previously reported.
19
 mp 167-170 
o
C; 
1
H NMR (400 MHz, 
CDCl3): δ 7.95-7.86 (m, 2H), 7.69-7.61 (m, 1H), 7.58-7.51 (m, 
2H), 7.48-7.39 (m, 2H), 7.13-7.05 (m, 2H), 5.94 (d, J = 10.5 Hz, 
1H), 5.85 (d, J = 10.5 Hz, 1H), 1.24 (s, 9H) ppm; 
13
C NMR 
(101 MHz, CDCl3): δ 163.7 (d, J = 251 Hz), 153.6, 136.8, 134.2, 
131.0 (d, J = 8.5 Hz), 129.6, 129.2, 125.9 (d, J = 3.5 Hz), 116.0 
(d, J = 21.5 Hz), 81.5, 73.3, 28.1 ppm; 
19
F NMR (376 MHz, 
CDCl3): δ -110.7 ppm; IR (ATR): νmax 3367, 2972, 1703, 1506, 
1309, 1140 cm
-1
; HRMS (ESI) 278.1150 (M + Na
+
. C13H18FNNaO3 
requires 278.1163 for the methanol adduct (-SO2Ph, +OMe)). 
 
[Benzenesulfonyl-(4-methoxy-phenyl)-methyl]-carbamic acid tert-
butyl ester (7f) 
4-Anisaldehyde (3.85 mL, 31.7 mmol) yielded 5.63 g (71%) as a 
white solid. Spectroscopic data was identical to that previously 
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19
 mp 156-158 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 8.05-
7.97 (m, 2H), 7.67-7.59 (m, 1H), 7.57-7.49 (m, 2H), 7.37 (d, J = 
8.5 Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 5.88 (d, J = 10.5 Hz, 1H), 
5.76 (d, J = 10.5 Hz, 1H), 3.82 (s, 3H), 1.24 (s, 9H) ppm; 
13
C 
NMR (101 MHz, CDCl3): δ 160.4, 153.2, 137.1, 134.0, 130.3, 
129.6, 129.2, 121.8, 114.4, 81.3, 73.6, 55.5, 28.1 ppm; IR (ATR): 
νmax 3361, 2967, 1695, 1503, 1310, 1162, 1149 cm
-1
; HRMS 
(ESI) 290.1350 (M + Na
+
. C14H21NNaO4 requires 290.1363 for 
the methanol adduct (-SO2Ph, +OMe)). 
 
(Benzenesulfonyl-pyridin-3-yl-methyl)-carbamic acid tert-butyl 
ester (7g) 
Nicotinaldehyde (7.8 mL, 83.0 mmol) yielded 9.09 g (47%) as a 
white solid. Spectroscopic data was identical to that previously 
reported.
25
 mp 168.5-171 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 8.68 
(dd, J = 5.0, 1.5 Hz, 1H), 8.66 (br d, J = 1.5 Hz, 1H) 7.96-7.90 (m, 
2H), 7.85 (ddd, J = 8.0, 2.0, 2.0 Hz, 1H), 7.68 (dd, J = 7.5, 7.5 Hz, 
1H), 7.57 (dd, J = 7.5, 7.5 Hz, 2H), 7.38 (dd, J = 8.0, 5.0 Hz, 1H), 
6.03 (d, J = 10.5 Hz, 1H), 5.98 (d, J = 10.5 Hz, 1H), 1.25 (s, 9H) 
ppm; 
13
C NMR (101 MHz, CDCl3): δ 153.6, 151.0, 150.1, 136.5, 
136.4, 134.5, 129.6, 129.4, 126.4, 123.7, 81.8, 72.0, 28.1 ppm; 
IR (ATR): νmax 3200, 3064, 2979, 1716, 1531, 1303, 1140 cm
-1
; 
HRMS (ESI) 239.1392 (M + H
+
. C12H19N2O3 requires 239.1390 
for the methanol adduct (-SO2Ph, +OMe)). 
 
[Benzenesulfonyl-(4-methyl-thiazol-5-yl)-methyl]-carbamic acid 
tert-butyl ester (7h) 
4-Methylthiazole-5-carbaldehyde (6.68 g, 52.5 mmol) yielded 
6.70 g (52%) as an off-white solid; mp 167-169 
o
C; 
1
H NMR 
(400 MHz, CDCl3): δ 8.80 (s, 1H), 7.93-7.87 (m, 2H), 7.67 (dd, J 
= 7.5, 7.5 Hz, 1H), 7.57 (dd, J = 7.5, 7.5 Hz, 2H), 6.26 (d, J = 10.5 
Hz, 1H), 5.59 (d, J = 10.5 Hz, 1H), 3.42 (s, 3H), 1.27 (s, 9H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 154.5, 153.5, 153.3, 136.2, 134.5, 
129.6, 129.4, 121.1, 81.9, 68.4, 28.1, 15.7 ppm; IR (ATR): νmax 
3153, 3071, 2976, 1707, 1535, 1302, 1140 cm
-1
; HRMS (ESI) 
259.1114 (M + H
+
. C11H19N2O3 requires 259.1111 for the 
methanol adduct (-SO2Ph, +OMe)). 
 
[Benzenesulfonyl-(1-methyl-1H-pyrazol-4-yl)-methyl]-carbamic 
acid tert-butyl ester (7i) 
1-Methyl-1H-pyrazole-4-carbaldehyde (1.5 g, 13.6 mmol) 
yielded 1.42 g (71%) as a white solid; mp 153.7-156.5 
o
C; 
1
H 
NMR (400 MHz, CDCl3): δ 7.95-7.89 (m, 2H), 7.66 (s, 1H), 7.66-
7.59 (m, 2H), 7.54 (dd, J = 7.5, 7.5 Hz, 2H), 5.95 (d, J = 10.5 Hz, 
1H), 5.73 (d, J = 10.5 Hz, 1H), 3.92 (s, 3H), 1.21 (s, 9H) ppm; 
13
C 
NMR (101 MHz, CDCl3): δ 153.5, 138.9, 136.6, 134.2, 130.7, 
129.7, 129.2, 125.0, 81.3, 67.4, 39.4, 28.1 ppm; IR (ATR): νmax 
3359, 2971, 1709, 1521, 1303, 1148, 1136 cm
-1
; HRMS (ESI) 
264.1305 (M + Na
+
. C11H19N3NaO3 requires 264.1319 for the 
methanol adduct (-SO2Ph, +OMe)). 
 
[Benzenesulfonyl-(4-cyano-phenyl)-methyl]-carbamic acid tert-
butyl ester (7j) 
4-Cyanobenzaldehyde (8.40 g, 64.1 mmol) yielded 14.9 g (94%) 
as a white solid. Spectroscopic data was identical to that 
previously reported.
20
 mp 151-154 
o
C; 
1
H NMR (400 MHz, 
CDCl3): δ 7.92 (d, J = 7.5 Hz, 2H), 7.73-7.64 (m, 3H), 7.62-7.53 
(m, 4H), 6.00 (d, J = 10.5 Hz, 1H), 5.93 (d, J = 10.5 Hz, 1H), 1.24 
(s, 9H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 153.5, 136.4, 135.1, 
134.6, 132.5, 129.8, 129.6, 129.4, 118.2, 113.8, 81.9, 77.4, 28.1 
ppm; IR (ATR): νmax 3369, 2962, 2235, 1701, 1506, 1308, 1143 
cm
-1
; HRMS (ESI) 285.1213 (M + Na
+
. C14H18N2NaO3 requires 
285.1210 for the methanol adduct (-SO2Ph, +OMe)).  
 
General procedure for the synthesis of N-Boc-δ-amino-β-
ketoesters 9 
To a solution of diisopropylamine (21.0 mmol) in THF (30 mL) 
at -78 °C was added n-BuLi (2.5M in hexanes, 21.0 mmol). The 
solution was stirred for 10 mins at -78 °C then a further 5 mins 
at room temperature. A solution of methyl acetoacetate (10.5 
mmol) in THF (6 mL) was added over 10 mins at -78 °C, then 
stirred for a further 40 mins. The imine was prepared by the 
portionwise addition of sulfone (3.50 mmol) to a suspension of 
NaH (7.00 mmol) in THF (12 mL) at room temperature. The 
subsequent mixture was stirred for 20 mins, then immediately 
transferred to the dianion mixture at -50 °C.  The reaction was 
stirred for 30 mins, then quenched with 10 M acetic acid in 
THF (2.5 mL). The mixture was warmed to room temperature 
and concentrated in vacuo. The residue was partitioned 
between EtOAc (30 mL) and water (25 mL). The aqueous layer 
was extracted with EtOAc (2 x 25 mL). Organics were 
combined, washed with water (50 mL) and brine (50 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (ethyl acetate/hexane) to 
afford the protected δ-amino-β-ketoester. 
 
5-tert-Butoxycarbonylamino-3-oxo-hexanoic acid methyl ester 
(9a) 
Sulfone 7a (1.00 g, 3.50 mmol) yielded 681 mg (76%) as a 
white solid after column chromatography (20% 
EtOAc/hexane); mp 55-56 °C; 
1
H NMR (400 MHz, CDCl3): δ 4.80 
(br s, 1H), 4.08-3.94 (m, 1H), 3.72 (s, 3H), 3.49 (d, J = 15.5 Hz, 
1H), 3.43 (d, J = 15.5 Hz, 1H), 2.79 (dd, J = 17.0, 5.5 Hz, 1H), 
2.69 (dd, J = 17.0, 5.5 Hz, 1H), 1.41 (s, 9H), 1.20 (d, J = 7.0 Hz, 
3H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 201.6, 167.6, 155.2, 
79.5, 52.5, 49.4, 49.1, 43.3, 28.5, 20.6 ppm; IR (ATR): νmax  
3366, 3312, 3000, 2976, 1737, 1702, 1679, 1535 cm
-1
; HRMS 
(ESI) 282.1321 (M + Na
+
. C12H21NNaO5 requires 282.1312). 
 
5-tert-Butoxycarbonylamino-3-oxo-octanoic acid methyl ester (9b) 
Sulfone 7b (400 mg, 1.28 mmol) yielded 238 mg (65%) as a 
white solid after column chromatography (20% 
EtOAc/hexane); mp 53-55 °C; 
1
H NMR (400 MHz, CDCl3): δ 4.78 
(d, J = 7.5 Hz, 1H), 3.95-3.79 (m, 1H), 3.72 (s, 3H), 3.50 (d, J = 
15.5 Hz, 1H), 3.43 (d, J = 15.5 Hz, 1H), 2.73 (d, J = 5.5 Hz, 2H), 
1.52-1.22 (m, 4H), 1.40 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H) ppm; 
13
C-
NMR (101 MHz, CDCl3): δ 201.9, 167.6, 155.6, 79.4, 52.5, 49.4, 
47.7, 47.3, 36.8, 28.5, 19.5, 13.9 ppm; IR (ATR): νmax  3288, 
2964, 2933, 1742, 1704, 1679, 1539, 1262, 1173 cm
-1
; HRMS 
(ESI) 310.1636 (M + Na
+
. C14H25NNaO5 requires 310.1625). 
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5-tert-Butoxycarbonylamino-6-methyl-3-oxo-heptanoic acid 
methyl ester (9c) 
Sulfone 7c (2.00 g, 6.39 mmol) yielded 917 mg (50%) as a white 
solid after column chromatography (20% EtOAc/hexane); mp 
60-62 °C; 
1
H NMR (400 MHz, CDCl3): δ 4.75 (br d, J = 9.0 Hz, 
1H), 3.81-3.71 (m, 1H), 3.73 (s, 3H), 3.56 (d, J = 16.0 Hz, 1H), 
3.47 (d, J = 16.0 Hz, 1H), 2.77 (dd, J = 16.0, 4.5 Hz, 1H), 2.69 
(dd, J = 16.0, 7.0 Hz, 1H), 1.91-1.79 (m, 1H), 1.42 (s, 9H), 0.90 
(d, J = 7.0 Hz, 6H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 202.0, 
167.7, 155.7, 79.4, 52.7, 52.4, 49.0, 45.6, 31.8, 28.4, 19.5, 18.6 
ppm; IR (ATR): νmax  3356, 2974, 2958, 1748, 1713, 1686, 1525, 
1307, 1128 cm
-1
; HRMS (ESI) 310.1618 (M + Na
+
. C14H25NNaO5 
requires 320.1625). 
 
5-tert-Butoxycarbonylamino-3-oxo-5-phenyl-pentanoic acid 
methyl ester (9d) 
Sulfone 7d (1.00 g, 2.89 mmol) yielded 672 mg (73%) as a 
white solid after column chromatography (20% 
EtOAc/hexane); mp 83.7-85.5 °C;
 1
H NMR (500 MHz, CDCl3): δ 
7.34-7.22 (m, 5H), 5.34 (br s, 1H), 5.10 (br s, 1H), 3.68 (s, 3H), 
3.42 (d, J = 15.5 Hz, 1H), 3.38 (d, J = 15.5 Hz, 1H), 3.17 (dd, J = 
16.5, 6.0 Hz, 1H), 3.04 (dd, J = 16.5, 6.0 Hz, 1H) 1.41 (s, 9H) 
ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.9, 167.4, 155.2, 141.2, 
128.8, 127.7, 126.3, 79.9, 52.5, 51.0, 49.5, 48.8, 28.4 ppm; IR 
(ATR): νmax  3393, 2978, 1752, 1718, 1681, 1170, 1152 cm
-1
; 
HRMS (ESI) 344.1463 (M + Na
+
. C17H23NNaO5 requires 
344.1468). 
 
5-tert-Butoxycarbonylamino-5-(4-fluoro-phenyl)-3-oxo-pentanoic 
acid methyl ester (9e) 
Sulfone 7e (5.00 g, 13.7 mmol) yielded 3.59 g (77%) as a white 
solid after column chromatography (15-20% EtOAc/hexane); 
mp 87-88.5 °C; 
1
H NMR (400 MHz, CDCl3): δ 7.30-7.23 (m, 2H), 
7.05-6.97 (m, Hz, 2H), 5.33 (br s, 1H), 5.13-5.01 (m, 1H), 3.69 
(s, 3H), 3.42 (d, J = 15.5 Hz, 1H), 3.38 (d, J = 15.5 Hz, 1H), 3.16 
(dd, J = 17.0, 6.0 Hz, 1H), 3.02 (dd, J = 17.0 Hz, 6.0 Hz, 1H), 1.41 
(s, 9H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.7, 167.4, 162.1 
(d, J = 247.0 Hz), 155.2, 137.2, 128.1 (d, J = 8.0 Hz), 115.6 (d, J = 
21.5 Hz), 80.1, 52.6, 50.4, 49.5, 48.7, 28.4 ppm; 
19
F NMR (376 
MHz, CDCl3): δ -116.7 ppm; IR (ATR): νmax  3306, 2982, 1741, 
1713, 1673, 1535, 1511, 1365, 1328, 1286, 1221, 1161, 999 
cm
-1
; HRMS (ESI) 340.1556 (M + H
+
. C17H23FNO5 requires 
340.1555). 
 
5-tert-Butoxycarbonylamino-5-(4-methoxy-phenyl)-3-oxo-
pentanoic acid methyl ester (9f) 
Sulfone 7f (3.00 g, 7.95 mmol) yielded 1.49 g (53%) as a yellow 
oil after column chromatography (15-20% EtOAc/hexane); 
1
H 
NMR (400 MHz, CDCl3): δ 7.24-7.19 (m, 2H), 6.89-6.84 (m, 2H), 
5.20 (br s, 1H), 5.11-5.01 (m, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 
3.43 (d, J = 16.0 Hz, 1H), 3.41 (d, J = 16.0 Hz, 1H), 3.15 (dd, J = 
16.5, 6.5 Hz, 1H), 3.05 (dd, J = 16.5, 6.5 Hz, 1H), 1.42 (s, 9H) 
ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.7, 167.3, 159.0, 155.0, 
133.3, 127.4, 114.1, 79.8, 55.3, 52.4, 50.5, 49.4, 48.8, 28.3 
ppm; IR (ATR): νmax 3356, 2974, 2839, 1748, 1708, 1679, 1512, 
1243, 1163, 1037 cm
-1
; HRMS (ESI) 352.1743 (M + H
+
. 
C18H26NO6 requires 352.1755). 
 
5-tert-Butoxycarbonylamino-3-oxo-5-pyridin-3-yl-pentanoic acid 
methyl ester (9g) 
Sulfone 7g (5.00 g, 14.4 mmol) yielded 2.58 g (56%) as an off-
white solid after column chromatography (100% ethyl 
acetate); mp 96.5-99.5 °C; 
1
H NMR (400 MHz, CDCl3): δ 8.58-
8.54 (m, 1H), 8.50 (dd, J = 4.5, 1.5 Hz, 1H), 7.64 (ddd, J = 8.0, 
1.5, 1.5 Hz, 1H), 7.26 (dd, J = 8.0, 4.5 Hz, 1H), 5.51 (br s, 1H), 
5.13 (br s, 1H), 3.69 (s, 3H), 3.45 (d, J = 15.5 Hz, 1H), 3.40 (d, J = 
15.5 Hz, 1H), 3.24 (dd, J = 17.0, 4.0 Hz, 1H), 3.08 (dd, J = 17.0, 
4.0 Hz, 1H), 1.41 (s, 9H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 
200.6, 167.3, 155.1, 148.9, 148.2, 136.9, 134.2, 123.5, 80.3, 
52.6, 49.3, 48.8, 48.1, 28.4 ppm; IR (ATR): νmax 3208, 2982, 
1756, 1709, 1542, 1365, 1282, 1178, 1082, 1005 cm
-1
; HRMS 
(ESI) 323.1594 (M + H
+
. C16H23N2O5 requires 323.1601). 
 
5-tert-Butoxycarbonylamino-5-(4-methyl-thiazol-5-yl)-3-oxo-
pentanoic acid methyl ester (9h) 
Sulfone 7h (5.00 g, 13.6 mmol) yielded 2.69 g (58%) as a pale 
red solid after column chromatography (50-100% ethyl 
acetate/hexane); mp 91.5-94 °C; 
1
H NMR (400 MHz, CDCl3): δ 
8.60 (s, 1H), 5.41 (dd, J = 14.0, 6.0 Hz, 1H), 5.27 (br s, 1H), 3.71 
(s, 3H), 3.46 (d, J = 15.5 Hz, 1H), 3.42 (d, J = 15.5 Hz, 1H), 3.21 
(dd, J = 17.5, 6.0 Hz, 1H), 3.06 (dd, J = 17.5, 6.0 Hz, 1H), 2.49 (s, 
3H), 1.41 (s, 9H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.2, 
167.2, 154.8, 150.5, 149.9, 132.7, 80.4, 52.7, 51.5, 49.4, 44.5, 
28.4, 15.5 ppm; IR (ATR): νmax 3214, 2976, 1752, 1719, 1701, 
1532, 1277, 1172, 1127, 1003 cm
-1
; HRMS (ESI) 343.1314 (M + 
Na
+
. C15H23N2O5S requires 343.1322). 
 
5-tert-Butoxycarbonylamino-5-(1-methyl-1H-pyrazol-4-yl)-3-oxo-
pentanoic acid methyl ester (9i) 
Sulfone 7i (1.3 g, 3.51 mmol) yielded 652 mg (57%) as a 
colourless oil after column chromatography (50-100% ethyl 
acetate/hexane); 
1
H NMR (400 MHz, CDCl3): δ 7.37 (s, 1H), 
7.30 (s, 1H), 5.22 (br s, 1H), 5.12-5.03 (m, 1H), 3.85 (s, 3H), 
3.73 (s, 3H), 3.48 (d, J = 15.5 Hz, 1H), 3.44 (d, J = 15.5 Hz, 1H), 
3.12 (dd, J = 17.0, 6.0 Hz, 1H), 3.05 (dd, J = 17.0, 6.0 Hz, 1H), 
1.44 (s, 9H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 201.1, 167.4, 
155.2, 137.2, 128.4, 122.5, 79.9, 52.5, 49.4, 48.4, 43.0, 39.1, 
28.4 ppm; IR (ATR): νmax 3355, 2976, 1744, 1705, 1512, 1365, 
1245, 1162, 1015cm
-1
; HRMS (ESI) 326.1697 (M + H
+
. 
C15H24N3O5 requires 326.1711). 
 
5-tert-Butoxycarbonylamino-5-(4-cyano-phenyl)-3-oxo-pentanoic 
acid methyl ester (9j) 
Sulfone 7j (2.00 g, 5.38 mmol) yielded 1.26 g (68%) as a white 
solid after column chromatography (15-25% EtOAc/hexane); 
mp 93-95.5 °C; 
1
H NMR (400 MHz, CDCl3): δ 7.64-7.60 (m, 2H), 
7.45-7.40 (m, 2H), 5.53 (br s, 1H), 5.13 (br s, 1H), 3.70 (s, 3H), 
3.43 (d, J = 15.5 Hz, 1H), 3.38 (d, J = 15.5 Hz, 1H), 3.22 (dd, J = 
17.5, 4.5 Hz, 1H), 3.05 (dd, J = 17.5, 4.5 Hz, 1H), 1.41 (s, 9H) 
ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.3, 167.3, 155.1, 147.0, 
132.6, 127.2, 118.8, 111.4, 80.4, 52.7, 50.5, 49.3, 47.9, 28.4 
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ppm; IR (ATR): νmax 3343, 2995, 2955, 2228, 1751, 1707, 1676, 
1525, 1271, 1249, 1166, 1152 cm
-1
; HRMS (ESI) 369.1421 (M + 
Na
+
. C18H22N2NaO5 requires 369.1421). 
 
General procedure for the synthesis of 2-spiropiperidines 11 
Protected δ-amino-β-ketoester (3.00 mmol) was stirred in 4M 
HCl in dioxane (45.0 mmol) for 3h at room temperature. The 
mixture was concentrated in vacuo to afford the hydrochloride 
salt which was used without further purification. 
To a suspension of hydrochloride salt (0.308 mmol) and ketone 
(1.54 mmol) in CH2Cl2 (1 mL), was added NaHCO3 (129 mg, 
1.54 mmol). The reaction was stirred for 16h at room 
temperature, then filtered and concentrated in vacuo. The 
residue was purified by column chromatography to afford 2-
spiropiperidin-4-ones. 
 
2,2,6-Trimethyl-4-oxo-piperidine-3-carboxylic acid methyl ester 
(11a) 
Hydrochloride salt of 9a (60 mg, 0.308 mmol) yielded 52 mg 
(85%, 2.5:1 dr) as a yellow oil without further purification; 
1
H 
NMR (500 MHz, CDCl3): δ 3.69 (s, 3H), 3.22 (d, J = 1.0 Hz, 1H), 
3.18 (dqd, J = 10.5, 6.5, 3.5 Hz, 1H), 2.47 (dd, J = 13.5, 10.5 Hz, 
1H), 2.32 (ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 1.26 (d, J = 6.5 Hz, 3H), 
1.18 (s, 3H), 1.09 (s, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 
205.7, 169.7, 66.8, 57.9, 52.3, 48.4, 46.9, 28.2, 26.1, 22.8 ppm; 
IR (ATR): νmax 2967, 1705, 1610, 1534, 1434, 1136 cm
-1
; HRMS 
(ESI) 200.1289 (M + H
+
. C10H18NO3 requires 200.1281). 
 
2-Methyl-4-oxo-1-aza-spiro[5.5]undecane-5-carboxylic acid methyl 
ester (11b) 
Hydrochloride salt of 9a (60 mg, 0.308 mmol) yielded 63 mg 
(85%, 7:1 dr) as a yellow oil. Aqueous work-up was performed, 
partitioning between ethyl acetate and 2N aq. NaOH; 
1
H NMR 
(500 MHz, CDCl3): δ 3.67 (s, 3H), 3.34 (br s, 1H), 3.15 (dqd, J = 
10.5, 6.5, 3.5 Hz, 1H), 2.51 (dd, J = 13.5, 10.5 Hz, 1H), 2.30 
(ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 1.60-1.30 (m, 10H), 1.25 (d, J = 
6.5 Hz, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 206.1, 169.5, 
65.8, 60.3, 52.1, 47.5, 47.2, 36.6, 33.7, 25.8, 22.9, 21.6, 21.1 
ppm; IR (ATR): νmax 2930, 2856, 1703, 1434, 1327, 1161 cm
-1
; 
HRMS (ESI) 240.1592 (M + H
+
. C13H22NO3 requires 240.1594). 
 
7-Methyl-9-oxo-6-aza-spiro[4.5]decane-10-carboxylic acid methyl 
ester (11c) 
Hydrochloride salt of 9a (65.8 mg, 0.337 mmol) yielded 32.4 
mg (43%, 5:1 dr) as a pink oil after column chromatography 
(trimethylamine deadened silica, 5% 
methanol/dichloromethane); 
1
H NMR (400 MHz, CDCl3): δ 3.69 
(s, 3H), 3.24 (d, J = 1.0 Hz, 1H), 3.06 (dqd, J = 10.5, 6.5, 3.5 Hz, 
1H), 2.43 (dd, J = 13.5, 10.5 Hz, 1H), 2.31 (ddd, J = 13.5, 3.5, 1.0 
Hz, 1H), 1.82-1.50 (m, 7H), 1.36 (m, 1H), 1.24 (d, J = 6.5 Hz, 3H) 
ppm; 
13
C NMR (101 MHz, CDCl3): δ 205.3, 169.9, 69.2, 66.1, 
52.3, 49.6, 47.6, 39.2, 36.1, 24.3, 23.7, 22.3 ppm; IR (ATR): νmax 
2957, 1704, 1435, 1329, 1268, 1192, 1158 cm
-1
; HRMS (ESI) 
226.1440 (M + H
+
. C12H20NO3 requires 226.1438). 
 
6-Methyl8-oxo-5-aza-spiro[3.5]nonane-9-carboxylic acid methyl 
ester (11d) 
Hydrochloride salt of 9a (72.4 mg, 0.371 mmol) yielded 52.6 
mg (67%, 2.5:1 dr) as a yellow oil after column 
chromatography (trimethylamine deadened silica, 5% 
methanol/dichloromethane); 
1
H NMR (400 MHz, CDCl3): δ 3.70 
(s, 3H), 3.55 (d, J = 1.0 Hz, 1H), 2.98 (dqd, J = 10.5, 6.5, 4.0 Hz, 
1H), 2.34 (dd, J = 13.5, 10.5 Hz, 1H), 2.27 (ddd, J = 13.5, 4.0, 1.0 
Hz, 1H), 2.01-1.75 (m, 6H), 1.23 (d, J = 6.5 Hz, 3H) ppm; 
13
C 
NMR (101 MHz, CDCl3): δ 204.4, 169.1, 65.4, 63.0, 52.3, 48.4, 
48.1, 32.4, 31.6, 22.5, 14.4 ppm; IR (ATR): νmax 2956, 1705, 
1434, 1329, 1193, 1166 cm
-1
; HRMS (ESI) 212.1275 (M + H
+
. 
C11H18NO3 requires 212.1281). 
 
2-Methyl-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-5-carboxylic acid 
methyl ester (11e) 
Hydrochloride salt of 9a (280 mg, 1.44 mmol) yielded 233 mg 
(67%, 4.5:1 dr) as a colourless oil after column 
chromatography (8% ethyl acetate/dichloromethane then 50% 
ethyl acetate/dichloromethane); 
1
H NMR (400 MHz, CDCl3): δ 
3.88 (ddd, J = 11.5, 10.0, 3.0 Hz, 1H), 3.72 (ddd, J = 11.5, 10.0, 
3.0 Hz, 1H), 3.67 (s, 3H), 3.63 (ddd, J = 11.5, 11.5, 4.0 Hz, 1H), 
3.56 (ddd, J = 11.5, 11.5, 4.0 Hz, 1H), 3.26 (d, J = 1.0 Hz, 1H), 
3.06 (dqd, J = 10.5, 6.0 Hz, 3.5 Hz, 1H), 2.48 (dd, J = 13.5, 10.5 
Hz, 1H), 2.30 (ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 1.67-1.54 (m, 2H), 
1.48-1.36 (m, 2H), 1.25 (d, J = 6.0 Hz, 3H) ppm; 
13
C NMR 
(101 MHz, CDCl3): δ 205.0, 168.9, 66.8, 63.3, 62.8, 58.2, 52.3, 
47.5, 46.9, 36.5, 33.6, 22.8 ppm; IR (ATR): νmax 2956, 2867, 
1703, 1435, 1333, 1162 cm
-1
; HRMS (ESI) 242.1386 (M + H
+
. 
C12H20NO4 requires 242.1387). 
 
4-Oxo-2-phenyl-1-aza-spiro[5.5]undecane-5-carboxylic acid methyl 
ester (11f) 
Hydrochloride salt of 9b (116 mg, 0.451 mmol) yielded 105 mg 
(78%, 7:1 dr) as a yellow oil after successively washing an ethyl 
acetate layer with water (15 times); 
1
H NMR (400 MHz, CDCl3): 
δ 7.48-7.27 (m, 5H), 4.11 (dd, J = 11.0, 4.0 Hz, 1H), 3.72 (s, 3H), 
3.41 (br s, 1H), 3.08 (dd, J = 13.5, 11.0, 1H), 2.53 (ddd, J = 13.5, 
4.0, 1.0 Hz, 1H), 1.76-1.29 (m, 10H) ppm; 
13
C NMR (101 MHz, 
CDCl3): δ 205.4, 169.5, 142.5, 128.9, 127.8, 126.7, 66.6, 60.4, 
55.5, 52.2, 46.3, 36.6, 33.3, 25.7, 21.5, 21.0 ppm; IR (ATR): νmax 
2930, 2855, 1702, 1434, 1327, 1192, 1162 cm
-1
; HRMS (ESI) 
302.1754 (M + H
+
. C18H24NO3 requires 302.1751). 
 
6-(4-Fluoro-phenyl)-2,2-dimethyl-4-oxo-piperidine-3-carboxylic 
acid methyl ester (11g) 
Hydrochloride salt of 9e (110 mg, 0.399 mmol) yielded 108 mg 
(97%, 1.8:1 dr) as a yellow oil without further purification; 
1
H 
NMR (500 MHz, CDCl3): δ 7.44 (m, 2H), 7.09-7.03 (m, 2H), 4.16 
(dd, J = 11.5, 3.5 Hz, 1H), 3.75 (s, 3H), 3.33 (d, J = 1.0 Hz, 1H), 
3.00 (dd, J = 13.5, 11.5 Hz, 1H), 2.50 (ddd, J = 13.5, 3.5, 1.0 Hz, 
1H), 1.24 (s, 3H), 1.21 (s, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): 
δ 204.7, 169.7, 162.4 (d, J = 247.0 Hz), 137.9 (d, J = 3.5 Hz), 
128.3 (d, J = 8.5 Hz), 115.8 (d, J = 21.5 Hz), 67.1, 58.0, 56.2, 
52.4, 46.0, 28.4, 26.0 ppm; 
19
F NMR (376 MHz, CDCl3): δ -
114.42 ppm; IR (ATR): νmax 2969, 1748, 1705, 1603, 1509, 1222, 
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1195, 1152, 1125 cm
-1
; HRMS (ESI) 280.1342 (M + Na
+
. 
C15H19FNO3 requires 280.1343). 
 
2-(4-Fluoro-phenyl)-4-oxo-1-aza-spiro[5.5]undecane-5-carboxylic 
acid methyl ester (11h) 
Hydrochloride salt of 9e (69.5 mg, 0.248 mmol) yielded 59 mg 
(75%, 5:1 dr) as a yellow oil after successively washing an ethyl 
acetate layer with water (5 times); 
1
H NMR (400 MHz, CDCl3): δ 
7.46-7.39 (m, 2H), 7.10-7.03 (m, 2H), 4.10 (dd, J = 11.5, 4.0 Hz, 
1H), 3.73 (s, 3H), 3.41 (br s, 1H), 3.04 (dd, J = 13.5, 11.5 Hz, 
1H), 2.52 (ddd, J = 13.5, 4.0, 1.0 Hz, 1H), 1.80-1.29 (m, 10H) 
ppm; 
13
C NMR (101 MHz, CDCl3): δ 205.1, 169.6, 162.3 (d, J = 
247.0 Hz), 138.4 (d, J = 3.0 Hz), 128.4 (d, J = 8.0 Hz), 115.8 (d, J 
= 21.0 Hz), 66.5, 60.3, 54.8, 52.3, 46.3, 36.6, 33.4, 25.7, 21.6, 
21.1 ppm; 
19
F NMR (376 MHz, CDCl3): δ -114.7 ppm; IR (ATR): 
νmax 2933, 2856, 1705, 1600, 1510, 1439, 1329, 1224, 1159 cm
-
1
; HRMS (ESI) 320.1645 (M + H
+
. C18H23FNO3 requires 
320.1656). 
 
2-(4-fluoro-phenyl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11i) 
Hydrochloride salt of 9e (129 mg, 0.468 mmol) yielded 84.5 mg 
(56%, 2:1 dr) as a white solid after column chromatography 
(trimethylamine deadened silica, 20% ethyl 
acetate/dichloromethane); mp 110.5-113 
o
C; 
1
H NMR (500 
MHz, CDCl3): δ 7.45-7.40 (m, 2H), 7.11-7.06 (m, 2H), 4.09 (dd, J 
= 11.5, 3.5 Hz, 1H), 3.90 (ddd, J = 11.5, 10.5, 3.0 Hz, 1H), 3.81 
(ddd, J = 11.5, 10.5, 3.0 Hz, 1H), 3.74 (s, 3H), 3.72-3.64 (m, 2H), 
3.40 (d, J = 1.0 Hz, 1H), 3.06 (dd, J = 13.5, 11.5 Hz, 1H), 2.57 
(ddd, 13.5, 3.5, 1.0 Hz, 1H), 2.14 (br s, 1H), 1.81-1.75 (m, 1H), 
1.73 (ddd, J = 14.0, 10.5, 4.0 Hz, 1H), 1.59 (ddd, J = 14.0, 10.5, 
4.0 Hz, 1H), 1.52-1.46 (m, 1H) ppm; 
13
C NMR (101 MHz, CDCl3): 
δ 204.2, 169.0, 162.1 (d, J = 245.0 Hz), 138.8 (d, J = 3.0 Hz), 
128.3 (d, J = 14.0 Hz), 115.8 (d, J = 21.5 Hz), 67.0, 63.4, 62.8, 
58.3, 54.9, 52.5, 46.1, 36.7, 33.4 ppm; 
19
F NMR (376 MHz, 
CDCl3): δ -114.0 ppm; IR (ATR): νmax 2963, 2868, 1706, 1603, 
1511, 1223, 1160 cm
-1
; HRMS (ESI) 322.1445 (M + H
+
. 
C17H21FNO4 requires 322.1449), 344.1269 (M + Na
+
. 
C17H21FNO4 requires 344.1269). 
 
2-(4-Fluoro-phenyl)-4-oxo-9-thia-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11j) 
Hydrochloride salt of 9e (189 mg, 0.686 mmol) yielded 171 mg 
(63%, 1:1 dr) as a colourless oil after column chromatography 
(trimethylamine deadened silica, 10-20% ethyl 
acetate/hexane); 
1
H NMR (400 MHz, CDCl3): δ 7.45-7.39 (m, 
2H), 7.11-7.04 (m, 2H), 4.04 (dd, J = 11.0, 4.0 Hz, 1H), 3.73 (s, 
3H), 3.33 (br s, 1H), 3.22-3.12 (m, 1H), 3.04 (dd, J = 13.5, 11.0 
Hz, 1H), 3.06-2.93 (m, 1H), 2.56 (ddd, J = 13.5, 4.0, 0.5 Hz, 1H), 
2.41-2.32 (m, 2H), 2.12-1.93 (m, 2H), 1.84-1.77 (m, 2H), 1.70 
(ddd, J = 14.5, 11.5, 14.5 Hz, 1H) ppm; 
13
C NMR (101 MHz, 
CDCl3): δ 204.3, 169.0, 162.4 (d, J = 247.5 Hz), 137.8 (d, J = 3.5 
Hz), 128.3 (d, J = 8.0 Hz), 115.8 (d, J = 21.5 Hz), 67.4, 59.3, 54.4, 
52.5, 45.7, 37.3, 34.3, 23.4, 22.8 ppm; 
19
F NMR (376 MHz, 
CDCl3): δ -114.3 ppm; IR (ATR): νmax 2962, 2922, 1705, 1510, 
1226, 1196, 1161 cm
-1
; HRMS (ESI) 338.1205 (M + H
+
. 
C17H21FNO3S requires 338.1221). 
 
2-(4-Methoxy-phenyl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11k) 
Hydrochloride salt of 9f (757 mg, 2.63 mmol) yielded 290 mg 
(33%, 2:1 dr) as a pale red solid after column chromatography 
(0-80% ethyl acetate/cyclohexane); mp 118-121 
o
C;
 1
H NMR 
(400 MHz, CDCl3): δ 7.43-7.36 (m, 2H), 6.98-6.92 (m, 2H), 4.08 
(dd, J = 11.0, 3.5 Hz, 1H), 4.03-3.64 (m, 4H), 3.84 (s, 3H), 3.76 
(s, 3H), 3.42 (d, J = 1.0 Hz, 1H), 3.10 (dd, J = 13.5, 11.0 Hz, 1H), 
2.57 (ddd, J = 13.5, 3.5, 1.0 Hz, 1H-5), 2.15 (br s, 1H), 1.85-1.70 
(m, 2H), 1.65-1.44 (m, 2H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 
204.4, 168.9, 159.2, 134.1, 127.7, 114.2, 67.0, 63.3, 62.7, 58.2, 
55.3, 54.9, 52.3, 46.2, 36.6, 33.3 ppm; IR (ATR): νmax 3318, 
2965, 2947, 2865, 1732, 1701, 1515, 1297, 1243,1159, 1024 
cm
-1
. HRMS (ESI) 334.1637 (M + H
+
. C18H24NO5 requires 
334.1649). 
 
6-(3-pyridyl)-2,2-dimethyl-4-oxo-piperidine-3-carboxylic acid 
methyl ester (11l) 
Hydrochloride salt of 9g (80 mg, 0.310 mmol) yielded 70 mg 
(86%, 1.5:1 dr) as a yellow oil without further purification; 
1
H 
NMR (500 MHz, CDCl3): δ 8.65 (d, J = 2.0 Hz, 1H), 8.55 (dd, J = 
4.5, 2.0 Hz, 1H), 7.80 (ddd, J = 8.0, 2.0, 2.0 Hz, 1H), 7.31 (dd, J = 
8.0, 4.5 Hz, 1H), 4.21 (dd, J = 11.5, 4.0 Hz, 1H), 3.73 (s, 3H), 
3.13 (d, J = 1.0 Hz, 1H), 3.01 (dd, J = 13.5, 11.5 Hz, 1H), 2.52 
(ddd, J = 13.5, 4.0, 1.0 Hz, 1H), 1.24 (s, 3H), 1.22 (s, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 204.3, 169.7, 149.5, 148.8, 137.4, 
134.1, 123.9, 66.9, 58.0, 54.2, 52.2, 45.4, 28.3, 25.8 ppm; IR 
(ATR): νmax 2969, 1707, 1429, 1197, 1153 cm
-1
; HRMS (ESI) 
263.1393 (M + Na
+
. C14H19N2O3 requires 263.1390).  
 
4-Oxo-2-pyridin-3-yl-9-oxa-1-aza-spiro[5.5]undecane-5-carboxylic 
acid methyl ester (11m)  
Hydrochloride salt of 9g (1.50 g, 5.81 mmol) yielded 1.40 g 
(79%, 1.5:1 dr) as a yellow oil after column chromatography 
(50% ethyl acetate/dichloromethane then 100% ethyl acetate); 
1
H NMR (400 MHz, CDCl3): δ 8.69 (d, J = 2.0 Hz, 1H), 8.58 (dd, J 
= 5.0, 2.0 Hz, 1H), 7.82 (ddd, J = 8.0, 2.0, 2.0 Hz, 1H), 7.34 (dd, J 
= 8.0, 5.0 Hz, 1H), 4.17 (dd, J = 11.5, 3.5 Hz, 1H), 3.90 (ddd, J = 
11.5, 11.5, 2.5 Hz, 1H), 3.81 (ddd, J = 11.5, 11.5, 2.5 Hz, 1H), 
3.74 (s, 3H), 3.74-3.64 (m, 2H), 3.41 (d, J = 0.5 Hz, 1H), 3.09 
(dd, J = 13.5, 11.5 Hz, 1H), 2.61 (ddd, J = 13.5, 3.5, 0.5 Hz, 1H), 
2.20 (br s, 1H), 1.83-1.69 (m, 2H), 1.65-1.56 (m, 1H), 1.53-1.45 
(m, 1H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 203.5, 168.9, 149.4, 
148.7, 137.2, 134.0, 123.8, 67.0, 63.3, 62.7, 58.3, 53.1, 52.5, 
45.3, 36.5, 33.2 ppm; IR (ATR): νmax 2952, 2872, 1706, 1428, 
1337, 1195, 1166 cm
-1
; HRMS (ESI) 305.1486 (M + H
+
. 
C16H21N2O4 requires 305.1496). 
 
4-Oxo-2-pyridin-3-yl-1,9-diaza-spiro[5.5]undecane-5,9-dicarboxylic 
acid 9-benzyl ester 5-methyl ester (11n) 
Hydrochloride salt of 9g (145 mg, 0.562 mmol) yielded 145 mg 
(67%, 2:1 dr) as a yellow oil after column chromatography 
(50% ethyl acetate/dichloromethane then 100% ethyl acetate); 
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1
H NMR (400 MHz, CDCl3): δ 8.66 (br s, 1H), 8.56 (dd, J = 5.0, 
1.5 Hz, 1H), 7.78 (ddd, J = 8.0, 1.5, 1.5 Hz, 1H), 7.37-7.26 (m, 
6H), 5.10 (s, 2H), 4.20-4.06 (m, 1H), 3.92-3.75 (m, 2H), 3.71 (s, 
3H), 3.45-3.16 (m, 2H), 3.30 (d, J = 0.5 Hz, 1H), 3.07 (dd, J = 
13.5, 11.5 Hz, 1H), 2.60 (ddd, J = 13.5, 3.0, 0.5 Hz, 1H), 1.91-
1.34 (m, 4H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 203.1, 168.8, 
155.2, 149.5, 148.6, 137.0, 136.7, 133.9, 128.6, 128.1, 127.9, 
123.8, 67.2, 66.8, 58.8, 53.2, 52.5, 45.0, 39.5, 39.0, 35.5, 32.3 
ppm; IR (ATR): νmax 2951, 1694, 1427, 1246, 1164 cm
-1
; HRMS 
(ESI) 438.2032 (M + H
+
. C24H28N3O5 requires 438.2023). 
 
4-Oxo-2-pyridin-3-yl-9-thia-1-aza-spiro[5.5]undecane-5-carboxylic 
acid methyl ester (11o) 
Hydrochloride salt of 9g (103.6 mg, 0.402 mmol) yielded 77.5 
mg (75%, 0.95:1 dr) as a yellow oil after column 
chromatography (50% ethyl acetate/hexane then 100% ethyl 
acetate). 
1
H NMR (400 MHz, CDCl3): δ 8.68-8.64 (m, 1H), 8.58-
8.54 (m, 1H), 7.79 (ddd, 8.0, 2.0, 2.0 Hz, 1H), 7.35-7.28 (m, 1H), 
4.10 (br s, 1H), 3.71 (s, 3H), 3.33 (d, J = 1.0 Hz, 1H), 3.20-3.09 
(m, 1H), 3.05 (dd, 13.5, 11.5 Hz, 1H), 3.06-2.90 (m, 1H), 2.58 
(ddd, 13.5, 4.0, 1.0 Hz, 1H), 2.40-2.28 (m, 2H), 2.12-2.05 (m, 
1H), 1.82-1.77 (m, 2H), 1.70 (ddd, J = 14.5, 11.5, 3.0, 1H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 203.6, 168.9, 149.5, 148.7, 137.1, 
134.0, 123.8, 67.4, 59.3, 52.7, 52.5, 44.9, 37.2, 34.2, 23.3, 22.7 
ppm; IR (ATR): νmax 3310, 2952, 2920, 1703, 1424, 1268, 1195, 
1162 cm
-1
; HRMS (ESI) 321.1260 (M + H
+
. C16H21N2O3S requires 
321.1267).  
 
2-(4-Methyl-thiazol-5-yl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11p) 
Hydrochloride 9i (99 mg, 0.356 mmol) yielded 86 mg (75%, 1:1 
dr) as an off-white solid after column chromatography (50% 
ethyl acetate/dichloromethane then 100% ethyl acetate); mp 
98-101 
o
C; 
1
H NMR (400 MHz, CDCl3): δ 8.67 (s, 1H), 4.41 (dd, J 
= 11.0, 3.5 Hz, 1H), 3.90-3.76 (m, 2H), 3.73 (s, 3H), 3.71-3.64 
(m, 2H), 3.38 (br s, 1H), 3.05 (dd, J = 13.5, 11.0 Hz, 1H), 2.63 
(ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 2.47 (s, 3H), 1.80-1.54 (m, 3H), 
1.51-1.41 (m, 1H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 202.5, 
168.7, 150.2, 149.9, 133.0, 66.8, 63.3, 62.7, 58.1, 52.6, 48.8, 
47.1, 36.5, 33.4, 16.6 ppm; IR (ATR): νmax 2953, 2865, 1706, 
1435, 1338, 1255, 1196, 1165 cm
-1
; HRMS (ESI) 325.1201 (M + 
H
+
. C15H21N2O4S requires 325.1217). 
 
2-(1-Methyl-1H-pyrazol-4-yl)-4-oxo-9-oxa-1-aza-
spiro[5.5]undecane-5-carboxylic acid methyl ester (11q) 
Hydrochloride salt of 9h (203 mg, 0.776 mmol) yielded 119 mg 
(50%, 2.5:1 dr) as a yellow oil after column chromatography (0-
50% ethanol/ethyl acetate); 
1
H NMR (400 MHz, CDCl3): δ 7.52 
(s, 1H), 7.40 (s, 1H), 4.13 (dd, J = 11.0, 3.5 Hz, 1H), 4.00-3.63 
(m, 4H), 3.91 (s, 3H), 3.72 (s, 3H), 3.38 (d, J = 1.0 Hz, 1H), 2.97 
(dd, J = 13.5, 11.0 Hz, 1H), 2.63 (ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 
1.80-1.67 (m, 2H), 1.61-1.44 (m, 2H) ppm; 
13
C-NMR (101 MHz, 
CDCl3): δ 203.7, 168.7, 137.1, 127.6, 123.8, 67.1, 63.2, 62.7, 
58.0, 52.3, 47.4, 46.1, 39.0, 36.5, 33.3 ppm; IR (ATR): νmax 3282, 
3248, 1704, 1562, 1435, 1296, 1218, 1159 cm
-1
; HRMS (ESI) 
308.1594 (M + H
+
. C15H22N3O4 requires 308.1605). 
 
6-(4-Cyano-phenyl)-8-oxo-5-aza-spiro[3.5]nonane-9-carboxylic 
acid methyl ester (11r) 
Hydrochloride salt of 9j (102 mg, 0.362 mmol) yielded 67.5 mg 
(63%, 1:1 dr) as a yellow oil after column chromatography 
(33% ethyl acetate/hexane); 
1
H NMR (400 MHz, CDCl3): δ 7.69-
7.64 (m, 2H), 7.57-7.50 (m, 2H), 4.04 (dd, J = 11.5, 3.5 Hz, 1H), 
3.76 (s, 3H), 3.65 (d, J = 1.0 Hz, 1H), 2.86 (dd, J = 13.5, 11.5 Hz, 
1H), 2.52 (ddd, J = 13.5, 3.5, 1.0 Hz, 1H), 2.29-2.20 (m, 1H), 
2.15-2.05 (m, 1H), 2.04-1.86 (m, 4H) ppm; 
13
C-NMR (101 MHz, 
CDCl3): δ 202.9, 169.0, 147.1, 132.8, 127.5, 118.7, 111.8, 65.1, 
63.0, 56.0, 52.5, 46.8, 32.6, 31.7, 14.2; IR (ATR): νmax 3313, 
2952, 2227, 1707, 1607, 1435, 1290, 1197, 1165 cm
-1
; HRMS 
(ESI) 299.1383 (M + H
+
. C17H19N2O3 requires 299.1390).  
 
6-(4-Cyano-phenyl)-8-oxo-2-oxa-5-aza-spiro[3.5]nonane-9-
carboxylic acid methyl ester (11s)
 
Hydrochloride salt of 9j (93 mg, 0.330 mmol) yielded 42.8 mg 
(43%, 1.6:1 dr) as a yellow oil after column chromatography 
(60% ethyl acetate/hexane); 
1
H NMR (400 MHz, CDCl3): δ 7.70-
7.66 (m, 2H), 7.57-7.51 (m, 2H), 4.92 (d, J = 7.5 Hz, 1H), 4.61 (d, 
J = 7.5 Hz, 1H), 4.56 (d, J = 6.5 Hz, 1H), 4.50 (d, J = 6.5 Hz, 1H), 
4.02 (dd, J = 11.5, 3.5 Hz, 1H), 3.93 (d, J = 1.5 Hz, 1H), 3.79 (s, 
3H), 2.72 (dd, J = 13.5, 11.5 Hz, 1H), 2.56 (ddd, J = 13.5, 3.5, 1.5 
Hz, 1H) ppm; 
13
C-NMR (101 MHz, CDCl3): δ 200.9, 167.9, 146.3, 
132.9, 127.5, 118.6, 112.3, 80.9, 80.1, 62.9, 62.4, 56.1, 53.0, 
47.5 ppm; IR (ATR): νmax 3302, 2874, 2228, 1717, 1608, 1441, 
1345, 1297 1225 cm
-1
; HRMS (ESI) 301.1179 (M + H
+
. 
C16H17N2O4 requires 301.1183). 
 
General procedure for the synthesis of N-Boc imines 12 
A suspension of benzenesulfonyl carbamic ester (8.15 mmol), 
K2CO3 (48.9 mmol) and Na2SO4 (57.1 mmol) in THF (82 mL) was 
stirred at reflux for 3h. The mixture was cooled to rt, filtered 
through a sintered funnel and concentrated in vacuo. The 
imine was used without further purification.  
 
(4-Fluoro-benzylidene)-carbamic acid tert-butyl ester (12e) 
Sulfone 7e (1.12 g, 3.07 mmol), K2CO3 (2.54 g, 18.4 mmol) and 
Na2SO4 (3.05 g, 21.5 mmol) gave the title compound (635 mg, 
2.86 mmol, 93% yield) as a white solid. Spectroscopic data was 
identical to that previously reported.
19
 
1
H NMR (400 MHz, 
CDCl3): δ 8.85 (s, 1H), 7.96-7.90 (m, 2H), 7.18-7.11 (m, 2H), 
1.58 (s, 9H) ppm. 
 
(4-Methoxy-benzylidene)-carbamic acid tert-butyl ester (12f) 
Sulfone 7f (1.07 g, 2.84 mmol), K2CO3 (2.35 g, 17.0 mmol) and 
Na2SO4 (2.83 g, 19.9 mmol) gave the title compound (601 mg, 
2.56 mmol, 90% yield) as a white solid. Spectroscopic data was 
identical to that previously reported.
19
 
1
H NMR (400 MHz, 
CDCl3): δ 8.87 (s, 1H), 7.91-7.85 (m, 2H), 6.98-6.91 (m, 2H), 
3.86 (s, 3H), 1.57 (s, 9H) ppm. 
 
(4-Methyl-thiazol-5-ylmethylene)-carbamic acid tert-butyl ester 
(12h) 
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Sulfone 7h (3.00 g, 8.15 mmol), K2CO3 (6.75 g, 48.9 mmol) and 
Na2SO4 (8.11 g, 57.1 mmol) gave the title compound (1.81 g, 
8.07 mmol, 99% yield) as an orange oil. 
1
H NMR (400 MHz, 
CDCl3): δ 9.17 (d, J = 0.5 Hz, 1H), 8.88 (s, 1H), 2.68 (s, 3H), 1.55 
(s, 9H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 162.3, 161.8, 161.7, 
158.2, 129.7, 82.7, 27.8, 16.3 ppm; IR (ATR): νmax 2982, 2931, 
1705, 1600, 1512, 1366, 1243, 1150 cm
-1
; HRMS (ESI) 281.0917 
(M + Na+. C11H18N2NaO3S requires 281.0930 for the methanol 
adduct). 
 
(4-Cyano-benzylidene)-carbamic acid tert-butyl ester (12j) 
Sulfone 7j (1.15 g, 3.13 mmol), K2CO3 (2.59 g, 18.8 mmol) and 
Na2SO4 (3.11 g, 21.9 mmol) gave the title compound (723 mg, 
3.13 mmol, 100% yield) as a white amorphous solid. 
Spectroscopic data was identical to that previously reported.
20
 
1
H NMR (400 MHz, CDCl3): δ 8.82 (s, 1H), 8.03-7.97 (m, 2H), 
7.79-7.74 (m, 2H), 1.58 (s, 9H) ppm. 
 
(4-Trifluoromethyl-benzylidene)-carbamic acid tert-butyl ester 
(12k) 
Sulfone 7k (1.09 g, 2.63 mmol), K2CO3 (2.18 g, 15.8 mmol) and 
Na2SO4 (2.61 g, 18.4 mmol) gave the title compound (710 mg, 
2.60 mmol, 99% yield) as a white amorphous white solid. 
Spectroscopic data was identical to that previously reported.
19
 
1
H NMR (400 MHz, CDCl3): δ 8.87 (s, 1H), 8.02 (d, J = 8.2 Hz, 
2H), 7.73 (d, J = 8.2 Hz, 2H), 1.59 (s, 9H) ppm. 
 
General procedure for the one-pot synthesis of 2-spiropiperidines 
11 
Neat TiCl4 (4.56 mmol) was added dropwise to a solution of 
imine (1.14 mmol) in CH2Cl2 (11.4 mL) at -78 
o
C. Chan’s diene 
(2.28 mmol) was added dropwise and the mixture was stirred 
for 30 mins at -78 
o
C. MeOH (18.2 mmol) was added and the 
mixture was stirred at rt for 4h. Ketone (5.70 mmol) and 
NaHCO3 (45.6 mmol) were sequentially added, and the 
reaction was stirred overnight at rt. The reaction was 
quenched with 1.59M citric acid in MeOH (11.4 mmol), and the 
mixture was cooled to 0 
o
C. Water (8 mL) was carefully added, 
followed by dilution with CH2Cl2 (10 mL) and the mixture was 
stirred vigorously for 30 mins at rt. The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). 
Organics were combined, washed with sat. aq. NaHCO3 (20 
mL) and brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified by 
column chromatography.   
 
2-(4-Methyl-thiazol-5-yl)-4-oxo-9-thia-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11t) 
Imine 12h (149 mg, 0.659 mmol), TiCl4 (289 μL, 2.64 mmol), 
Chan’s diene (343 mg, 1.32 mmol), MeOH (424 μL, 10.5 mmol), 
tetrahydro-4H-thiopyran-4-one (383 mg, 3.30 mmol) and 
NaHCO3 (2.22 g, 26.4 mmol). Purification by column 
chromatography (40% EtOAc/hexane) gave the title compound 
(123 mg, 0.362 mmol, 55% yield) as a red oil; 
1
H NMR (400 
MHz, CDCl3): δ 8.67 (s, 1H), 4.43-4.32 (m, 1H), 3.72 (s, 3H), 3.31 
(br. s, 1H), 3.16-3.06 (m, 1H), 3.02 (dd, J = 13.7, 11.5 Hz, 1H), 
3.05-2.94 (m, 1H), 2.62 (ddd, J = 13.7, 3.5, 1.0 Hz, 1H), 2.48 (s, 
3H), 2.42-2.33 (m, 2H), 2.12-1.75 (m, 4H), 1.71 (ddd, J = 14.5, 
11.7, 3.2 Hz, 1H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 202.6, 
168.7, 150.3, 149.8, 133.1, 67.2, 59.1, 52.6, 48.4, 46.9, 37.2, 
34.3, 23.3, 22.7, 15.7 ppm; IR (ATR): νmax 3314, 2952, 2922, 
1705, 1434, 1415, 1315, 1266, 1196, 1163 cm
-1
; HRMS (ESI) 
341.0990 (M + H+. C15H21N2O3S2 requires 341.0988). 
 
2-(4-Methyl-thiazol-5-yl)-4-oxo-1,9-diaza-spiro[5.5]undecane-5,9-
dicarboxylic acid 9-benzyl ester 5-methyl ester (11u) 
Imine 12h (119 mg, 0.527 mmol), TiCl4 (231 μL, 2.11 mmol), 
Chan’s diene (260 mg, 1.05 mmol), MeOH (341 μL, 8.43 mmol), 
1-Z-4-piperidone (615 mg, 2.64 mmol) and NaHCO3 (1.77 g, 
21.1 mmol). Purification by column chromatography (40% 
EtOAc/hexane then 80% EtOAc/hexane) gave the title 
compound (107 mg, 0.473 mmol, 45% yield) as an orange oil; 
1
H NMR (400 MHz, CDCl3): δ 8.67 (s, 1H), 7.39-7.27 (m, 5H), 
5.11 (s, 2H), 4.46-4.33 (m, 1H), 3.95-3.76 (m, 2H), 3.73 (s, 3H), 
3.43-3.24 (m, 2H), 3.29 (br. s, 1H), 3.05 (dd, J = 13.5, 11.2 Hz, 
1H), 2.70-2.60 (m, 1H), 2.46 (s, 3H), 2.04 (br. s, 1H), 1.93-1.37 
(m, 4H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 202.3, 168.7, 155.2, 
150.3, 149.9, 136.7, 132.9, 128.6, 128.2, 128.1, 67.3, 66.7, 
58.5, 52.7, 48.9, 47.0, 39.5, 39.1, 35.6, 32.4, 15.7 ppm; IR 
(ATR): νmax 2951, 1698, 1432, 1247, 1165 cm
-1
; HRMS (ESI) 
458.1747 (M + H+. C23H28N3O5S requires 458.1744). 
 
2-(4-Cyano-phenyl)-4-oxo-1,9-diaza-spiro[5.5]undecane-5,9-
dicarboxylic acid 9-benzyl ester 5-methyl ester (11v) 
Imine 12j (131 mg, 0.570 mmol), TiCl4 (250 μL, 2.28 mmol), 
Chan’s diene (296 mg, 1.14 mmol), MeOH (368 μL, 9.12 mmol), 
1-Z-4-piperidone (664 mg, 2.85 mmol) and NaHCO3 (1.92 g, 
22.8 mmol). Purification by column chromatography (30% 
EtOAc/hexane) gave the title compound (62 mg, 0.137 mmol, 
24% yield) as a yellow oil; 
1
H NMR (400 MHz, CDCl3): δ 7.71-
7.64 (m, 2H), 7.59-7.52 (m, 2H), 7.39-7.28 (m, 5H), 5.10 (s, 2H), 
4.19-4.08 (m, 1H), 3.92-3.75 (m, 2H), 3.73 (s, 3H), 3.46-3.34 (m, 
1H), 3.32 (d, J = 1.0 Hz, 1H), 3.32-3.18 (m, 1H), 3.03 (dd, J = 
13.7, 11.5 Hz, 1H), 2.61 (dd, J = 13.7, 3.5 Hz, 1H), 1.89-1.37 (m, 
4H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 203.0, 169.0, 155.2, 
146.8, 136.7, 132.8, 128.6, 128.2, 128.0, 127.5, 118.6, 112.0, 
67.3, 66.7, 58.9, 55.0, 52.6, 45.2, 39.5, 39.0, 35.6, 32.3 ppm; IR 
(ATR): νmax 2952, 2227, 1694, 1431, 1231, 1164, 1120 cm
-1
; 
HRMS (ESI) 462.2025 (M + H+. C26H28N3O5 requires 462.2023), 
484.1841 (M + Na+. C26H27N3NaO5 requires 484.1843). 
 
4-Oxo-2-(4-trifluoromethyl-phenyl)-1-aza-spiro[5.5]undecane-5-
carboxylic acid methyl ester (11w) 
Imine 12k (314 mg, 1.15 mmol), TiCl4 (504 μL, 4.60 mmol), 
Chan’s diene (598 mg, 2.30 mmol), MeOH (743 μL, 18.4 mmol), 
cyclohexanone (595 μL, 5.75 mmol) and NaHCO3 (3.86 g, 46.0 
mmol). Purification by column chromatography (10% 
EtOAc/hexane) gave an inseparable mixture of product and 
cyclohexanone. The mixture was dissolved in EtOAc (20 mL) 
and washed with water (10 x 10 mL), dried (MgSO4), filtered 
and concentrated to give the title compound (117 mg, 0.322 
mmol, 28% yield) as a yellow oil; 
1
H NMR (400 MHz, CDCl3): δ 
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7.67-7.55 (m, 4H), 4.18 (dd, J = 11.2, 3.8 Hz, 1H), 3.73 (s, 3H), 
3.42 (br. s, 1H), 3.06 (dd, J = 13.5, 11.2 Hz, 1H), 2.57 (ddd, J = 
13.5, 3.8, 1.0 Hz, 1H), 1.78-1.29 (m, 10H) ppm; 
13
C NMR 
(101 MHz, CDCl3): δ 204.6, 169.5, 146.4, 130.0 (q, J = 32.4 Hz), 
127.1, 125.9 (q, J = 3.5 Hz), 124.1 (q, J = 273 Hz), 66.6, 60.3, 
54.9, 52.3, 45.8, 36.6, 33.3, 25.6, 21.5, 21.0 ppm; 
19
F NMR (376 
MHz, CDCl3): δ -62.4 ppm; IR (ATR): νmax 2933, 2857, 1706, 
1324, 1164, 1123, 1068 cm
-1
; HRMS (ESI) 370.1606 (M + H+. 
C19H23F3NO3 requires 370.1625). 
 
2,2-Dimethyl-6-(4-methyl-thiazol-5-yl)-4-oxo-piperidine-3-
carboxylic acid methyl ester (11x) 
Imine 12h (321 mg, 1.42 mmol), TiCl4 (623 μL, 5.68 mmol), 
Chan’s diene (738 mg, 2.84 mmol), MeOH (917 μL, 22.7 mmol), 
acetone (630 μL, 8.52 mmol) and NaHCO3 (4.77 g, 56.8 mmol). 
Purification by column chromatography (75% EtOAc/hexane) 
gave the title compound (96 mg, 0.341 mmol, 24% yield) as a 
red solid; mp 101.5-106 °C; 
1
H NMR (400 MHz, CDCl3): δ 8.64 
(s, 1H), 4.62 (dd, J = 11.0, 3.5 Hz, 1H), 3.74 (s, 3H), 3.61 (s, 1H), 
2.59 (dd, J = 13.5, 3.5 Hz, 1H), 2.43-2.40 (m, 1H), 2.41 (s, 3H), 
1.44 (s, 3H), 1.32 (s, 3H) ppm; 
13
C NMR (101 MHz, CDCl3): δ 
202.3, 168.4, 151.2, 148.7, 134.1, 66.9, 56.8, 52.0, 49.5, 48.9, 
30.0, 22.7, 15.5 ppm; IR (ATR): νmax 2953, 1747, 1713, 1435, 
1341, 1276, 1192, 1121 cm-1; HRMS (ESI) 283.1112 (M + H+. 
C13H19N2O3S requires 283.1111). 
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